Global Eylea Market and Forecast to 2030

Apelo Consulting has released a report on “Global Eylea Market (By Disorder, Product, End User, Region), Company profiles and Market Dynamics – Forecast to 2030”

Transcript

1. 2024-2030 GLOBAL EYLEA MARKET ANALYSIS Comprehensive Market Overview | Growth Drivers | Segmentation | Regional Insights | Future Outlook Prepared by Apelo Consulting October 2025 1 Global Eylea Market Analysis Apelo Consulting
2. EXECUTIVE SUMMARY ~7% CAGR The global Eylea market was valued at USD 9,714 Million in 2024, projected to reach USD 14,545 Million by 2030. Robust growth driven by rising retinal diseases, aging demographics, and innovative treatment formats. Widespread adoption across all regions and key end user segments. Backed by strong clinical evidence and robust safety profile. Key Growth Rate 2024-2030 Forecast Period 2 Global Eylea Market Analysis | Executive Summary Apelo Consulting
3. Eylea (aflibercept) is a potent anti-VEGF therapy that inhibits abnormal blood vessel growth in the retina Administered via intravitreal injection by ophthalmologists Redefined standards for retinal disease management over the past decade Backed by robust clinical evidence with a consistent safety profile Key Benefit Improves vision and reduces risk of blindness in patients with retinal diseases 3 Global Eylea Market Analysis | What is Eylea? Apelo Consulting What is Eylea? (Aflibercept) Wet Age-related Macular Degeneration (AMD) Leading cause of vision loss in adults over 50 Diabetic Macular Edema (DME) Complication of diabetes affecting vision Diabetic Retinopathy (DR) Progressive damage to retina due to diabetes Retinal Vein Occlusion (RVO) Blockage of veins carrying blood from retina Myopic Choroidal Neovascularization (mCNV) Complication of severe near-sightedness Primary Medical Applications:
4. Aging Population Rising global aging population fueling increased incidence of age-related macular degeneration and other retinal disorders. Market Growth Drivers Diabetes Prevalence Escalating prevalence of diabetes worldwide, leading to higher rates of diabetic eye conditions requiring treatment. Safety Profile Strong clinical evidence and consistent safety profile earning trust among ophthalmologists and patients alike. Product Innovation Major companies focusing on new product launches and delivery formats to expand treatment options and meet evolving patient needs. Healthcare Infrastructure Advancement in healthcare infrastructure and greater screening/diagnosis capabilities across developed and emerging markets. Projected Market Growth from 2024-2030 USD 9,714M → USD 14,545M Representing ~7% CAGR 4 Global Eylea Market Analysis | Market Growth Drivers Apelo Consulting
5. Wet Age-related Macular Degeneration (AMD) Market leader in 2024 Over 200 million affected globally, projected to reach 300 million by 2040 Market Segmentation by Disorder Diabetic Macular Edema (DME) Growing segment driven by diabetes prevalence Approximately 21 million people affected globally Myopic Choroidal Neovascularization (mCNV) Low double-digit market share in 2024 Rising prevalence in East Asia with improved diagnosis Other indications include Diabetic Retinopathy (DR) and Retinal Vein Occlusion (RVO) Key Insight AMD prevalence is increasing due to aging global population, driving market growth for Eylea through 2030 5 Global Eylea Market Analysis | Market Segmentation by Disorder Apelo Consulting
6. Largest market share in 2024 Favored for convenience and streamlined dispensing Growing preference among healthcare providers Reduces preparation time and dosing errors Prefilled Syringe Package Segmentation: By Product Type Popular in cost-sensitive markets Compatible with standard intravitreal administration Preferred in regions with less advanced healthcare infrastructure More economical option where cost constraints are critical Vial Package Manufacturers expanding production facilities in emerging markets Supply chain optimization reducing costs and improving efficiency Regional adaptations based on healthcare infrastructure and cost considerations Market Expansion Trends 6 Global Eylea Market Analysis | Product Type Segmentation Apelo Consulting
7. Hospitals Largest market segment due to advanced ophthalmic care infrastructure Well-established specialized eye care units with experienced retinal specialists On-site pharmacy services creating ideal setting for Eylea administration Retail Pharmacies Others segment includes: Specialty clinics, ambulatory surgical centers, and ophthalmology practice Segmentation: By End User Fast-growing segment driven by decentralized care models Increasing patient need for convenient treatment access Rise in prefilled syringes format optimized for pharmacy dispensing 7 Global Eylea Market Analysis | End User Segmentation Apelo Consulting
8. North America - Market leader in 2024, driven by robust healthcare infrastructure, supportive reimbursement policies, and high awareness of anti-VEGF therapy. Europe - ~25% market share, backed by advanced therapeutics adoption and favorable policies in Germany, France, and the UK. Asia Pacific - Fastest growth potential, driven by increasing diabetes prevalence and aging populations, especially in China, Japan, and India. Latin America, Middle East & Africa - Emerging opportunities with expanding healthcare access. Regional Growth Spotlight Surging diabetes rates and improving healthcare infrastructure Regional Market Analysis 8 Global Eylea Market Analysis | Regional Market Analysis Apelo Consulting Asia Pacific: Highest CAGR
9. AMD Patients Globally (2024) Increasing diagnosis rates, emerging markets expansion, and new treatment formats driving future market growth Growth Opportunities Key Market Highlights Wet AMD dominance: Over 200 million people affected globally, projected to reach 300 million by 2040. Diabetic Macular Edema: Affects approximately 21 million people worldwide, driving significant market growth. Prefilled syringes: Captured highest market share in 2024, expanding into emerging markets. Hospitals: Dominant end-user segment with specialized ophthalmic care infrastructure. 200 M+ DME Patients Worldwide 21 M 9 Global Eylea Market Analysis | Key Market Highlights Apelo Consulting
10. Challenges Cost pressures in healthcare systems worldwide Competition from biosimilars and alternative therapies Limited access in low-resource settings Growth Drivers Aging global population driving increased incidence of age- related eye disorders Rising diabetes prevalence, particularly in developing economies Enhanced healthcare infrastructure and reimbursement policies Increased disease awareness and early screening programs Market Dynamics & Future Outlook Future Outlook (2024-2030) Strategic Forecast Continued expansion into new therapeutic indications Regional production scale-up in emerging markets Innovation in delivery formats and treatment regimens Greater accessibility through improved distribution networks 10 Global Eylea Market Analysis | Market Dynamics & Future Outlook Apelo Consulting
11. THANK YOU www.apeloconsulting.com